OrganoTherapeutics

𝐀𝐫𝐞 𝐭𝐡𝐞𝐫𝐞 𝐢𝐦𝐦𝐮𝐧𝐞 𝐜𝐞𝐥𝐥𝐬 𝐢𝐧 𝐛𝐫𝐚𝐢𝐧 𝐨𝐫𝐠𝐚𝐧𝐨𝐢𝐝𝐬❓ In this perspective published earlier this year, we discuss immune cell integration into brain organoids 🧠 Traditional brain organoids lack immune system cells, limiting their ability to mimic the brain's natural environment accurately. In a new generation of organoids, various brain regions and immune cells are integrated, providing deeper insights into conditions like cancer, autoimmunity, and mental disorders 🔬 This innovation could revolutionize our understanding and treatment of neuroinflammatory diseases 💊 🔗 https://lnkd.in/gThgUE7J #immunesystem #organoids #perspective

🌟 Looking forward to participate in the DeepTech Ventures Demo Day 2024 🚀 #Deeptech #startup #innovation

🗓 You're still on time to watch our latest Webinar on midbrain organoids 🧠 On 19/06, our CEO Jens Schwamborn gave an online talk about midbrain organoids, dopamine and Parkinson's Disease studies in a Webinar organized by Immusmol. The recording is still available on-demand, so if you missed it, you're still on time to watch it 💻 🔗 To see the video, visit https://lnkd.in/eSbwj2Zw #Webinar #organoids

Happy to work together with Singleron Biotechnologies 🤝 #research #sequencing #organoids

Our team members, Isabel Rosety and Sònia Sabaté Soler recently attended the Keystone Symposia on Neurodegenerative Diseases organized by Keystone Symposia on Molecular & Cellular Biology in Santa Fe, New Mexico. They represented OrganoTherapeutics by sharing their posters with our peers. We are happy to keep connecting with academia and industry researchers, and sharing our latest results and advances with the community 🤝 #KSNeurodegen24 #KSNeuroImmune24

💻 𝐔𝐩𝐜𝐨𝐦𝐢𝐧𝐠 𝐖𝐞𝐛𝐢𝐧𝐚𝐫 𝐰𝐢𝐭𝐡 𝐈𝐦𝐦𝐮𝐬𝐦𝐨𝐥 This Wednesday 19/06, our CEO Jens Schwamborn will present our model and advances in a Webinar organized by Immusmol. The talk will focus on modeling Parkinson's Disease and quantifying dopamine released by our midbrain organoids 🧠 🔗 If you want to learn about Parkinson's Disease models and dopamine production, don't hesitate to register ➡ https://lnkd.in/eSbwj2Zw #dopamine #organoids #parkinsonsdisease

𝐍𝐞𝐰 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐏𝐫𝐢𝐚𝐯𝐨𝐢𝐝 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐚𝐧𝐝 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 𝐚𝐠𝐠𝐫𝐞𝐠𝐚𝐭𝐢𝐨𝐧 🧠 OrganoTherapeutics attended the #BIO2024 organized by the Biotechnology Innovation Organization in San Diego, USA 🌎. We are thrilled to announce an emerging collaboration with Priavoid GmbH to investigate how Priavoids #peptides resolve protein #aggregates in #Parkinsonsdisease patient-specific midbrain organoids. #BIO2024 #biotech Philipp Buerling

We are happy to be featured in #TheElevator 🚀 The Elevator is a video series available in RTL Play created by Silicon Luxembourg with the support of Orange Luxembourg. Each video shows an elevator pitch presented by entrepreneurs and members of Startups in Luxembourg, which takes place in the beautiful panoramic elevator in Pfaffenthal, Luxembourg 🌿 In the latest episode, our Project Lead Scientist, Isabel Rosety, talks about our work at OrganoTherapeutics and summarizes our research approach ⚗ 🔗 For more information visit https://lnkd.in/eEKytcZm #research #luxembourg #startup #elevatorpitch

See you at #BIO2024 on June 3-6 💼 ✈ Our CEO, Jens Schwamborn, will attend this year's BIO International Convention in San Diego, California, on June 3-6, 2024. The BIO International is the largest convention for Biotech industry leaders, making it a great environment for networking and envisioning new partnerships and collaborations. We are excited to attend and learn about the advances and initiatives of our biotech industry peers 🌎 Looking forward to connect and collaborate 🤝 #BIO2024 #biotech #research

👨🔬 Traditional cell culture methods have many advantages, but also limitations such as the low 3D complexity compared to human organs. Exciting breakthroughs over the last years have made organoid models great systems of higher complexity and human origin 🧠. In this review article from Nature Reviews Neurology, Eichmüller & Knoblich discuss the cutting-edge use of brain organoids to model conditions like Alzheimer's, Parkinson's, and Huntington's disease. Organoids offer a promising platform for understanding disease mechanisms, screening potential therapeutics, and even personalizing treatment approaches. At OrganoTherapeutics, we're at the forefront of this research, using midbrain organoids to study Parkinson's disease progression and develop innovative therapies. Dive into the latest advances and future prospects in this rapidly evolving field 🚀. 🔗 https://lnkd.in/d7HeEBaH #organoids #neurology #parkinsons